Please confirm that you would like to log out of Medscape.
If you log out, you will be required to enter your username and password the next time you visit.
Log outCancel
ENDOEarly Use of Triple Drug Cocktail Improves Ovulation in PCOSA treatment regimen combining two insulin sensitizers with an antiandrogenic agent may improve ovulation rates and metabolic parameters in girls with polycystic ovary syndrome before they were sexually active.
Medscape Medical News, April 11, 2017
ENDO'Bioidentical' Oral Alternative to Compound Hormones on HorizonNew oral fixed-dose combinations of 17-β estradiol and natural progesterone are being developed that, if approved, will offer a regulated alternative to compounded hormonal therapy for menopause symptoms.
Medscape Medical News, April 10, 2017
ENDOAbaloparatide Best in 'Really High-Risk' Osteoporosis Patients As anticipated US approval for a new anabolic agent, abaloparatide, for osteoporosis is delayed by 3 months, one expert discussed how he thinks the agent will best fit into the armamentarium.
New Diabetes Drugs and the Cost, Benefit of TreatmentWith so many choices emerging to treat type 2 diabetes, experts debated the advantages and risks of conventional and cutting-edge
options at ENDO 2017 and had some key takeaways to improve care.
Popular News from Endo 2016
Endocrine Society Advises Against Compounded Hormone UseA new scientific statement details the science of hormonal compounds for treating menopausal symptoms, sexual dysfunction,
and thyroid conditions, emphasizing the superiority of FDA-approved products.